Lund March 26, 2015

# EXINI signs BSI-agreement with university hospital RWTH Aachen

**It is with great satisfaction EXINI signs the renowned university hospital RWTH Aachen as a referential hospital for use of the software EXINI bone$^{BSI}$ in automated calculation of BSI-value (Bone Scan Index) in quantification of bone metastases in prostate cancer (mCRPC).**

Establishing referential hospitals is of strategic importance seeking to implement awareness and use of BSI in clinical workflow and development of new drugs for treatment of mCRPC.

*"BSI is an interesting imaging biomarker due to its potential to reflect treatment response in mCRPC. We are currently evaluating its clinical merits and limitations. As soon as the BSI has been validated clinically, it is likely to become standard in evaluations of bone-metastatic prostate cancer",* remarks Medical Director, Professor Axel Heidenreich M.D., Department of Urology RWTH Aachen.

*"To be able to count Aachen amongst EXINI's clients is a great honour, since professor Heidenreich is a leading person within treatment development of bone-metastatic prostate cancer,"* comments Magnus Aurell, CEO, EXINI Diagnostics AB.

**More on RWTH Aachen and Professor Axel Heidenreich**

RWTH Aachen is one of Germany's premier university hospitals with a highly acclaimed Department of Urology (Focus 2015) regarded as one of Europe's best clinics in treating mCRPC. Head of Department, Professor Heidenreich, takes a leading position within the GWG-CRPC, (German Working Group on Castration Resistant Prostate Cancer) gathering Germany's cutting edge cancer clinics. Professor Heidenreich has also chaired the EAU committee (European Association of Urology) responsible for establishing guidelines for treatment of prostate cancer.

**www.ukaachen.de**

**More on Bone Scan Index (BSI)**

BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate- or breast cancer.

Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI bone$^{BSI}$ is the only software capable of extracting BSI-values for both these purposes.

**www.bonescanindex.org**
**www.exini.com/software/exini-bone-bsi/**

**For more information, please contact:**
Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com

**About EXINI Diagnostics AB (publ)**

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market Nasdaq First North and has about 600 shareholders. Consensus acts as Certified Adviser.